Talk:Belantamab mafodotin

FDA IND withdrawn for Belantamab Mafodotin
This page should be updated to indicate that GSK withdrew the US marketing application for relapsed/refractory multiple myeloma indication per the FDA's request after the DREAMM-3 trial. 156.111.108.150 (talk) 17:43, 5 June 2023 (UTC)